WuXi Biologics expands issued share capital through option exercises

WuXi Biologics (Cayman) Inc. disclosed an increase in its issued ordinary shares on November 26, 2025. This was primarily due to the exercise of share options under its Pre-IPO Share Option Scheme. The total number of issued shares rose from 4,113,734,981 to 4,117,744,981.

Specifically, 1,010,000 new shares were issued from the exercise of share options by participants at an issue price of HK$1.29 per share. This represents a 0.02455% increase from the existing issued shares. Additionally, 3,000,000 new shares were issued to a director of the issuer, also from the exercise of share options under the same scheme, at the same price of HK$1.29 per share. This accounted for a 0.07293% increase.

These changes reflect the continued exercise of share options from the company's Pre-IPO Share Option Scheme, which was adopted on January 5, 2016, and subsequently amended on August 10, 2016. The company confirmed that all conditions for listing were met, and proceeds from the share issues were duly received.